NO20053911L - Diazepinderivater som er nyttige som LFA inhibitorer. - Google Patents

Diazepinderivater som er nyttige som LFA inhibitorer.

Info

Publication number
NO20053911L
NO20053911L NO20053911A NO20053911A NO20053911L NO 20053911 L NO20053911 L NO 20053911L NO 20053911 A NO20053911 A NO 20053911A NO 20053911 A NO20053911 A NO 20053911A NO 20053911 L NO20053911 L NO 20053911L
Authority
NO
Norway
Prior art keywords
lfa
inhibitors
derivatives useful
diazepine derivatives
icam
Prior art date
Application number
NO20053911A
Other languages
English (en)
Other versions
NO20053911D0 (no
Inventor
Berndt Oberhauser
Gottfried Meingassner
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0301561A external-priority patent/GB0301561D0/en
Priority claimed from GB0323976A external-priority patent/GB0323976D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20053911D0 publication Critical patent/NO20053911D0/no
Publication of NO20053911L publication Critical patent/NO20053911L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Farmasøytisk aktive diazepaner, som f.eks. er nyttige ved behandling av forstyrrelser eller sykdommer mediert av LFA-l/ICAM-1, LFA-l/ICAM-2, LFA-l/ICAM-3 eller LFA-l/JAM-1 interaksjoner.
NO20053911A 2003-01-23 2005-08-22 Diazepinderivater som er nyttige som LFA inhibitorer. NO20053911L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0301561A GB0301561D0 (en) 2003-01-23 2003-01-23 Organic compounds
GB0323976A GB0323976D0 (en) 2003-10-13 2003-10-13 Organic compounds
PCT/EP2004/000514 WO2004065382A1 (en) 2003-01-23 2004-01-22 Diazepanes derivatives useful as lfa inhibitors

Publications (2)

Publication Number Publication Date
NO20053911D0 NO20053911D0 (no) 2005-08-22
NO20053911L true NO20053911L (no) 2005-10-24

Family

ID=32773971

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053911A NO20053911L (no) 2003-01-23 2005-08-22 Diazepinderivater som er nyttige som LFA inhibitorer.

Country Status (19)

Country Link
US (1) US7419976B2 (no)
EP (1) EP1590342A1 (no)
JP (1) JP4644655B2 (no)
KR (1) KR20050095618A (no)
AR (1) AR042740A1 (no)
AU (1) AU2004205504B2 (no)
BR (1) BRPI0406884A (no)
CA (1) CA2509764A1 (no)
CO (1) CO5580804A2 (no)
EC (1) ECSP055917A (no)
MX (1) MXPA05007846A (no)
MY (1) MY141850A (no)
NO (1) NO20053911L (no)
NZ (1) NZ540867A (no)
PE (1) PE20040941A1 (no)
PL (1) PL376540A1 (no)
RU (1) RU2347783C2 (no)
TW (1) TWI311557B (no)
WO (1) WO2004065382A1 (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101278522B1 (ko) 2004-12-02 2013-06-25 다이이찌 산쿄 가부시키가이샤 7원환 화합물 및 그 제조법 및 의약 용도
GB0507918D0 (en) * 2005-04-19 2005-05-25 Novartis Ag Organic compounds
WO2010126968A1 (en) * 2009-04-28 2010-11-04 Optmed, Inc. Compositions and methods for treating or preventing urolithiasis and conditions associated therewith

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399599B1 (en) * 1999-10-13 2002-06-04 Novartis Ag Substituted 2-oxo-1,4-diazacycloalkanes
ECSP003707A (es) * 1999-10-13 2002-05-23 Novartis Ag Diazepanes
AR030817A1 (es) * 2000-10-02 2003-09-03 Novartis Ag Derivados de diazacicloalcanodiona
KR20030051882A (ko) 2000-11-28 2003-06-25 제넨테크, 인크. Ｌｆａ-1 대항제 화합물

Also Published As

Publication number Publication date
EP1590342A1 (en) 2005-11-02
PL376540A1 (pl) 2006-01-09
ECSP055917A (es) 2005-11-22
JP2006515335A (ja) 2006-05-25
KR20050095618A (ko) 2005-09-29
RU2347783C2 (ru) 2009-02-27
US20060148780A1 (en) 2006-07-06
JP4644655B2 (ja) 2011-03-02
US7419976B2 (en) 2008-09-02
CO5580804A2 (es) 2005-11-30
PE20040941A1 (es) 2005-01-24
CA2509764A1 (en) 2004-08-05
NZ540867A (en) 2007-09-28
TW200418817A (en) 2004-10-01
MY141850A (en) 2010-07-16
MXPA05007846A (es) 2006-02-10
WO2004065382A1 (en) 2004-08-05
TWI311557B (en) 2009-07-01
AR042740A1 (es) 2005-06-29
BRPI0406884A (pt) 2006-01-03
AU2004205504B2 (en) 2007-09-20
RU2005126459A (ru) 2007-02-27
NO20053911D0 (no) 2005-08-22
AU2004205504A1 (en) 2004-08-05

Similar Documents

Publication Publication Date Title
CY1119480T1 (el) Παραγωγα ρετιναλης και μεθοδοι για τη χρηση αυτων για τη θεραπευτικη αντιμετωπιση διαταραχων της ορασης
DOP2006000252A (es) Profarmacos mutuos de glucosamina y glucosamina/anti-inflamatorio, composiciones, y metodos
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
CY1112238T1 (el) Αναστολεις μιτωτικης κινεσινης και μεθοδοι χρησης αυτων
ATE482213T1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
MX2009009463A (es) Preparacion de una pelicula de rapida disolucion/desintegracion que tiene una alta proporcion de ingrediente activo.
DK1789398T3 (da) 2-amino-quinazolin derivater anvendelige som inhibitorer af B-sekretase (BACE)
UY29246A1 (es) Nuevos compuestos
DE602005020611D1 (de) Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
NO20081788L (no) Cyklopropylaminer som modulatorer av histamin-H3-reseptoren
NO20074431L (no) Pyrrolopyrimidiner nyttige som proteinkinaseinhibitorer
ATE451376T1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
ECSP088821A (es) Derivados de tioxantina y su uso como inhibidores de la mpo
ATE353013T1 (de) Trizyklische pyrazolderivate, verfahren zu ihrer herstellung und ihre verwendung als antitumor mittel
NO20076447L (no) Bicykliske derivater som modulatorer av ionekanaler
ECSP077421A (es) Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1
CY1112281T1 (el) Αναστολεις διπεπτιδυλ πεπτιδασης για τη θεραπεια του διαβητη
WO2007027761A3 (en) Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease
BRPI0613859A8 (pt) compostos derivados de nitrocatecol, seu uso e seu processo de preparação, bem como composição farmacêutica
MA27880A1 (fr) Derives de tetrahydrocarbazole et leur utilisation pharmaceutique
NO20055907L (no) Fremgangsmate for behandling av en angstforstyrrelse
WO2005009387A3 (en) Azepine derivatives as pharmaceutical agents
CR11065A (es) Administracion semanal de inhibidores de peptidasa de dipeptidilo
NO341679B1 (no) Substituerte pyridylamidforbindelser, fremstilling av slike og farmasøytiske sammensetninger inneholdende slike, samt anvendelse som modulatorer av histamin H3-reseptoren
WO2006020680A3 (en) Heterocyclic compounds as pharmaceutical agents

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application